The USA Transcatheter Valve Replacement (TAVR) Interventional landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2021-2026)
The USA Transcatheter Valve Replacement (TAVR) report is the first-ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional radiology, Interventional cardiology, and Cardiothoracic surgery departments from academic/university hospitals, community teaching hospitals, non-teaching hospitals, and private practice in the USA.
The report covers:
Transcatheter valve replacement procedures: aortic valve, mitral valve, and pulmonary valve replacements for applications such as regurgitation and stenosis
Procedure trends: stages of the disease, artery location, performing departments, route of access used for the intervention, and type of interventions
Insights on hospital structure and utilization, physician treatment selection criteria, current and upcoming policies for diagnosis and treatment, and payer coverage are delved into.
Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.
Future trends such as an expansion of indications of TAVR for low-risk patients with symptomatic aortic stenosis and the introduction of new valve-in-valve (ViV) TAVI, a re-intervention technique, emergence techniques for mitral regurgitation such as transcatheter mitral annuloplasty, transcatheter edge-to-edge mitral repair (TEER), transcatheter mitral valve chordal repair are covered. Next-generation transcatheter valves that are developing features such as lower profile, easier positioning/ repositioning, and re-capturability to reduce procedural complications are potential game-changers to watch out for in the growing TAVR interventional devices market.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as Clinical trial of Edwards SAPIENS 3 Transcatheter Heart Valve and Commander delivery system; FDA approval of Portico Transcatheter aortic valve implantation (TAVI) system from Abbott are covered in the report
What’s in it for you?
This report will help transcatheter valve replacement (TAVR) interventional device companies understand the aortic valve stenosis intervention landscape, procedural and technology trends, the brand perception, in the USA.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the TAVR interventional devices market.
The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model. REPORT COST: 5,000 USD Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.